Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine

G. Lambertenghi-Deliliers, A. T. Maiolo, C. Annaloro

Research output: Contribution to journalArticle

Abstract

Prolymphocytic leukemia (PL) is a morphologically distinct disease generally characterized by unsatisfactory therapeutic response and brief survival. Aggressive chemotherapy protocols including doxorubicin (DX) have been successfully used as alternatives to treatments usually effective in chronic lymphocytic leukemia (CLL). A patient with typical PL, resistant to regimens containing DX, was treated with 4-demethoxydaunorubicin (4-dm DNR), a new anthracycline analog derived from daunorubicin (DNR). The therapeutic response was rapid and impressive; furthermore 4-dm DNR combined with arabinosyl cytosine (Ara-C) produced a complete remission which is unusual in PL.

Original languageEnglish
Pages (from-to)199-201
Number of pages3
JournalCancer
Volume54
Issue number2
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine'. Together they form a unique fingerprint.

  • Cite this

    Lambertenghi-Deliliers, G., Maiolo, A. T., & Annaloro, C. (1984). Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine. Cancer, 54(2), 199-201.